Daiwa Securities Group Inc. Tricida, Inc. Transaction History

Daiwa Securities Group Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$7.31 - $11.85 $709 - $1,149	97 Added 88.18%	207 $2,000
Q4 2020 Feb 04, 2021	SELL	$4.37 - $9.46 $742 - $1,608	-170 Reduced 60.71%	110 $1,000
Q4 2019 Jan 31, 2020	SELL	$29.6 - $43.71 $858 - $1,267	-29 Reduced 9.39%	280 $11,000
Q2 2019 Jul 24, 2019	BUY	$31.16 - $39.46 $1,277 - $1,617	41 Added 15.3%	309 $12,000
Q1 2019 Apr 26, 2019	SELL	$19.96 - $38.62 $1,417 - $2,742	-71 Reduced 20.94%	268 $10,000
Q4 2018 Feb 05, 2019	BUY	$23.57 - $32.33 $7,990 - $10,959	339 New	339 $8,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

Stay updated on Daiwa Securities Group Inc. with notifications on news.